Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment

Clinical Cancer Research

Volumn 19, Issue 21, 2013, Pages 6030-6038

  Morgan, Gareth J ^a   Davies, Faith E ^a   Gregory, Walter M ^b   Bell, Susan E ^b   Szubert, Alexander J ^b   Cook, Gordon ^c   Drayson, Mark T ^d   Owen, Roger G ^c   Ross, Fiona M ^e   Jackson, Graham H ^f   Child, J Anthony ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHROMOSOME ANALYSIS; DRUG DOSE INCREASE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; JAW OSTEONECROSIS; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CHROMOSOME ABERRATIONS; DIPHOSPHONATES; HUMANS; MULTIPLE MYELOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84887115062     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3211     Document Type: Article

References (34)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111: 2516-20.
2. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiplemyeloma in the twenty-first century: a population-based study. J Clin Oncol 2010;28: 830-4.
3. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376: 1989-99.
4. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012;97: 442-50.
5. Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011;118: 1231-8.
6. Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis. Blood 2012;119: 7-15.
7. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 2007;62: 148-52.
8. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102: 1115-23.
9. Morgan GJ. Further analyses of the myeloma IX Study. Lancet 2011;378: 768-9.
10. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12: 335-48.
11. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120: 1067-76.
12. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108: 3289-94.
13. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354: 1021-30.
14. Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27: 1788-93.
15. Ludwig H, Adam Z, Tothova E, Hajek R, Labar B, Egyed M, et al. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 2010;95: 1548-54.
16. Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and highdose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010;115: 1113-20.
17. Sahebi F, Spielberger R, Kogut NM, Fung H, Falk PM, Parker P, et al. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 2006;37: 825-9.
18. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008;112: 3115-21.
19. Magarotto V, Palumbo A. Evolving role of novel agents for maintenance therapy in myeloma. Cancer J 2009;15: 494-501.
20. Morabito F, Gentile M, Mazzone C, Bringhen S, Vigna E, Lucia E, et al. Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. Eur J Haematol 2010;85: 181-91.
21. Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11: 1086-95.
22. Attal M, lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366: 1782-91.
23. McCarthy P, Owzar K, Hofmeister C, Hurd D, Hassoun H, Richardson P, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366: 1770-81.
24. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci M, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366: 1759-69.
25. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376: 2075-85.
26. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116: 679-86.
27. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30: 2946-55.
28. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119: 4375-82.
29. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115: 3416-7.
30. Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, et al. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/ dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol 2012;156: 326-33.
31. Korde N, Zingone A, Kwok M, Manasanch EE, Costello R, Zuchlinski D, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients [abstract]. In: 54th Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Abstract nr 732.
32. Palumbo A, Bringhen S, Villani O, Siniscalchi A, Russo E, Uccello G, et al. Carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma (MM) patients[abstract]. In: 54th Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Abstract nr 730.
33. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Hamadani M, Stewart AK, et al. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). In: 54th Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Abstract nr 332.
34. Kaufman JL, Shah JJ, Laubach JP, Mitchell AR, Sharp C, Lewis C , et al. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (mm): results of a phase 1 study. In: 54th Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. abstract nr 336.